Aim: This retrospective study is aimed to review demographic and clinical characteristics of IBD to elucidate the probable factors associating with IBD development in Taleghani Hospital in Iran since 2001 during a 12-year-period. Background: Ulcerative colitis (UC) and Crohn's disease (CD) are two major idiopathic entities of inflammatory bowel disease (IBD). Previous studies have reported an increased incidence of IBD in Middle East countries. Patients and methods: In the present study 1914 patients with UC, 318 patients with CD and 25 with indeterminate colitis (IC) were included. Demographic information, clinical features, extraintestinal manifestations, complications and extension of disease were collected and interpreted for all participants. According to the time of registration, patients were divided into seven groups. Statistical analysis was performed using the chi-square test. Results: In seven groups of IBD patients, disease registry was estimated for UC, CD, and total IBD during a 12-year-period. From 2001 to 2005, a relative increased registry was observed among UC patients. However, in the years 2006 and 2007 a significant reduction in the number of patients was reported. Then an increasing trend was observed in UC patients. UC presented mostly with diarrhea, hematochezia and bloody diarrhea, while most of CD patients complained of abdominal pain. Conclusion: Evaluation of data related to registered IBD patients in Iran shows that probable incidence and prevalence of IBD (UC and CD) is increasing compared to previous decades.
Introduction
1 Inflammatory bowel disease (IBD), including ulcerative colitis (UC), Crohn's disease (CD) and another rare disorder with an intermediate features is increasing in developing nations in the past two decades (2) . Different frequencies of IBD in male and female were reported (3) . The diagnosis of IBD has two age peaks. In most populations the first peak is between 15 to 30 years and the second peak of IBD occurs between ages 50 to 70 (4) . The major presenting symptoms in UC involving the colon, are bloody diarrhea, mucus in the stools, abdominal pain, and weight loss. The CD can affect any part of the digestive tract, however the terminal ileum is the commonest site for the disease. The CD clinically presents with abdominal pain, diarrhea and weight loss (5) . Extra intestinal manifestations (EIM), occurring in 25-40 percent of IBD patients, can be seen in any organ system, such as musculoskeletal, skin, hepatopancreatobiliary, ocular and renal systems. Musculoskeletal disorders have been detected as the most common EIM in IBD (6) . Due to the lack of a central data registry system in Iran, there have been few epidemiological studies and current time trends of IBD in Iran. Therefore, the incidence and prevalence remain unknown (7) (8) (9) (10) (11) (12) . The aim of this study was to review the demographic features and clinical characteristics, extra-intestinal manifestations, complications, extension of disease and diagnosis identifications in outpatients and inpatients with IBD who referred to Taleghani hospital within a 12-year-period.
Patients and Methods
During a 12-year-period (between 2001 and 2013), 2257 patient's data were recorded in a questionnaire, including demographic information, medical, family and habitual history, diagnosis, identification, signs and symptoms at onset as well as date of visit, extra intestinal manifestations, complications and colonoscopy reports at Taleghani Hospital, Tehran, Iran.
The interview was performed face to face by a trained practitioner. General information was retrieved from medical records of patients or by a trained gastroenterologist. Moreover, the additional information gathered by telephone contact. IBD was confirmed by a gastroenterologist in patients based on diagnostic, clinical, radiological, endoscopic and pathological criteria, suggested by Lennard Jones (13) . Data was entered into an access database which was designed according to our questionnaire and updated through referring IBD patients for determining any other changes such as hospitalization, drug use, colonoscopy, pathology, laboratory tests or even new disease. According to the time of registration, patients were divided into 7 groups Descriptive age data of patients were presented as mean ± standard deviation. Comparison of background variables such as gender, breast feeding history, smoking and familial history were performed using Chi-square test and P-value <0.05 was considered as significant. This study has been approved by the Ethics Committee of Shahid Beheshti Medical University, Tehran, Iran. Table 2) .
Results
Analyzing total data of the IBD registry in these years elucidated some clinical features of IBD in Iran. Table 3 shows the demographic and clinical features in IBD patients. In this study, 85% of UC and CD patients had a breast-feeding history during infancy. Among all patients, 93.4% patients with UC and 88.7% with CD had never smoked and 3.9% patients with UC and 6.6% with CD were current smokers. Familial history of IBD figure 3 . UC presented mostly with diarrhea (74.3%), on the other hand, most of CD patients complained of abdominal pain (72.4%).
The distribution of some symptoms defer statistically significant between IBD patients including abdominal pain and fever, which were more frequent in CD patients but diarrhea, bloody diarrhea, hematochezia and constipation had more frequency in UC patients.
Extraintestinal manifestations were reported in 59.9% of UC patients and 60.2% of CD patients. Musculoskeletal (26.8%) and skin (18.2%) disorders were the most common affected sites in IBD patients. Also, 8.1% of UC patients were diagnosed with sclerosing cholangitis. Extraintestinal manifestations of IBD are shown in Table 4 .
Major complications of UC were reviewed in this study (Figure 4 ), including dysplasia (1.1%), pouchitis (0.2%), intestinal perforation (0.5%), toxic mega colon (0.4%), stenosis (0.9%) and severe bleeding (3.4%). According to our finding, 25.6% of patients with CD had documented fistula. Colorectal cancer was determined in 1% of IBD patients (equally in UC and CD patients).
Extension of disease at diagnosis in UC patients was as follows: 30.8% proctitis, 40.2% left side 
Discussion
In this present survey, the number of registered UC patients was 5 times higher than CD patients. Similar to the fourfold higher incidence of ulcerative colitis than Crohn's disease in Japanese (14) , and Chinese cohorts (15) . IBD is relatively rare in Asia, but it is more common in western countries, especially more prevalent in CD than UC (16). However, according to recent studies, both diseases have been reported with an increase in number in eastern countries (17) . Generally, due to lifestyle changes, inflammatory bowel disease has an increasing trend in this study. Different clinical features of IBD in Iran from those in western countries might be due to the differences in their racial and geographic conditions. Therefore, analysis on the demographic, clinical characteristics, prevalence and incidence of patients with IBD may give some valuable clues to the diagnosis and management of the disease.
An equal gender distribution of CD in this data conflicted with Asian studies, which appear with a male-predominant (18) . On the other hand, the demographic finding of UC in Iran shows a slight female predominant, but in western and Asian studies there is an equal sex distribution in UC.
In our study CD was diagnosed at a younger age than UC. The peak age of onset in Iran appears to be in the 2 nd (21) . Further study is also needed to confirm the increasing number of developing IBD in breast-fed patients during infancy.
A high incidence of a positive familial history of IBD among first and second-degree relatives in this study indicated a genetic role in pathogenesis of IBD similar to reports from western countries (22) , and a study from Sri Lanka (23). Therefore, genetics plays an important role in the pathogenesis of IBD.
The exact relationship between genetic susceptibility and the role of the environment in the pathogenesis of IBD remain largely a mystery to researchers. Genetic susceptibility plays a key role in IBD development. Iranian patients with their different genetic reservoirs may demonstrate some novel characteristics for disease susceptibility.
C3435T polymorphism of the MDR1 gene has an association with UC in Iranian population as in western countries (24) . A probable association of the Fok I polymorphism in the VDR receptor gene and Crohn's susceptibility in Iranian population was observed (25) . CARD15/NOD2 gene was more frequent in CD patients than controls (26) .
NOD2 exonic variations in Iranian Crohn's disease patients in 2011 were studied. Eight novel mutations were identified in the NOD2 exons, but the pathophysiological importance of these variants remains unclear (27) .
To advance our understanding of the key determinants of IBD in the developed and developing world, future population-based studies with a focus on reporting incidence and/or prevalence of IBD stratified by gene-environmentphenotype interactions seem necessary.
According to previous studies, smoking is the strongest environmental risk factor of CD (28) . However, some nations with a high incidence of CD such as Canada and Sweden had a low prevalence of smoking in their populations. On the other hand, there is a high rate of smoking in Asian populations but a low incidence of CD (29) . Thus, smoking needs to be further clarified in the population of this study.
Firouzi et al. indicate that there is no association between appendectomy and development of CD and the protective effect in UC (30) . Rates of appendectomies have decreased in developed countries, whereas the incidence of UC has remained constant. Moreover, the role of appendectomy in the development of CD has not been manifested in the West and Asia (31) . Also, a decreased risk of developing UC due to appendectomy has been shown in the West, China and Japan (32, 33) . This shows that appendectomy does not play a crucial role in the development of CD and UC.
Tonsillectomy was not associated with either UC or CD disease. The inverse association between ulcerative colitis and combined oral contraceptive pill (OCP) or non-steroidal antiinflammatory drug (NSAID) in the Iranian population is noted (30) . These findings of the current study are consistent with those of Andersson et al. (34) .
According to this study, diarrhea, hematochezia and bloody diarrhea seem to be the most common symptoms in UC patients. In comparison, the Chinese studies reported diarrhea, abdominal pain and bloody diarrhea as chief complaints of UC. Abdominal pain, diarrhea, weakness and weight loss were the predominant complaints in patients of CD patients, consistent with the reports in Chinese study (31) .
The high incidence of extraintestinal manifestations in this study is similar to western countries and in contrast with other studies in Asia (35) . According to a study from Boston, musculoskeletal disorders have been suggested the most common EIM in IBD patients (6) . The knee was affected more than other joints in both diseases.
Low incidence of complications in this study differs from those in other studies from the West and Asia. Fistulating disease in patients with CD has been documented in a higher incidence than those reported from China (29) . A low incidence of colorectal cancer was similar to reports from Asian countries (36) , but careful follow-up in patients with extensive colitis lasting 8-10 years or more is needed.
The predominant form of UC was left-sided colitis and proctosigmoiditis, and exclusive proctitis was uncommon, consistent with reports from South Asian study (37) . Assessing the location of CD in these studies shows that CD is confined to colon predominantly. The lack of data registry system was the biggest limitation in Iran. This study could provide a clue to a trend toward an increased prevalence of IBD in Iran. As IBD has an increasing trend during recent years, it seems beneficial to set up a control registry system to save patients' data through the country. Since the etiology and pathogenesis of IBD are not fully understood, insight into the worldwide epidemiology of IBD is important to identify geographic patterns and time trends, highlight the burden of IBD globally, and determine possible environmental roles in IBD. As we move forward into the next two to three decades of IBD, we will face a series of challenges. We must:
1. Identify disease targets and patients who will benefit the most by certain classes of drugs.
2. Design treatment strategies that will decrease loss of response to therapy.
3. Identify individual risk factors for aggressive disease and treat those patients accordingly to change the natural history of disease.
4. Develop strategies that will minimize neoplastic and infectious risks of our targeted drug therapies.
